Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Song L, Wei X, Zhai Z, Wang A, et al. Eur J Haematol 2026 Apr 21. doi: 10.1111/ejh.70164.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Song L, Wei X, Zhai Z, Wang A, et al. Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Eur J Haematol 2026 Apr 21. doi: 10.1111/ejh.70164.
PMID: 42015516